iCAD' Xoft radiotherapy shows survival improvement in recurrent brain tumors

• iCAD (ICAD +2.3%) announces latest data demonstrating significant improvement in overall survival and local progression-free survival in patients with recurrent glioblastoma (GBM) treated with Xoft Intraoperative Radiotherapy (IORT) against external beam radiation therapy (EBRT). The complete results are being presented at European Association of Neurosurgical Societies virtual congress.
• The survival of patients in the IORT group ranged from 16 – 59 months after the initial GBM diagnosis, compared to 5.5-38.5 months survival of patients in EBRT group.
• "The latest results are extremely encouraging, as they underscore the potential of Xoft IORT for recurrent glioblastoma while illustrating the impact our innovative technology may have on the treatment of the most aggressive primary brain tumors," said Michael Klein, Chairman and CEO of iCAD.
• Lead Investigator of the study Dr Alexey Krivoshapkin further explains that "Intraoperative balloon electronic brachytherapy has the potential to deliver the required prescribed single focal dose that is equivalent to multiple sessions of EBRT while minimizing radiation dose to neighboring healthy tissue."
• iCAD is also exploring research on Xoft Brain IORT to multiple leading cancer centers worldwide and its other emerging applications, including the treatment of early-stage rectal tumors.
• https://seekingalpha.com/news/3623282-icad-xoft-radiotherapy-shows-survival-improvement-in-recurrent-brain-tumors-treatment